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Gallic Acid Reduces Experimental Colitis in Rats by 
Downregulation of Cathepsin and Oxidative Stress
Objective: Ulcerative colitis (UC) is an idiopathic inflammatory bowel disease (IBD) with common, repetitive inflammation 
of the colon and rectum, which is highly defined by loss of blood on colon mucosa, ulceration and acute inflammation. The 
present study aimed to investigate the potential protective effects of gallic acid (GA) through a 2,4,6-trinitrobenzene sulfonic 
acid (TNBS)-induced colitis rat model, using biochemical and histopathological parameters.
Materials and Methods: The study consisted of four groups, each including seven rats, namely control group, colitis group, 
colitis-GA 50 mg/kg group and colitis-GA 100 mg/kg group. Colon tissue samples were analyzed for malondialdehyde 
(MDA), myeloperoxidase (MPO), cathepsin B and cathepsin L values.
Results: Tissue MDA, MPO, cathepsin L and cathepsin B values increased significantly in colitis group (p=0.028, p=0.038, 
p=0.024, p=0.019, respectively). However, MDA, MPO, cathepsin L and cathepsin B values showed a significant decrease 
in animals with GA (at a dose of 100 mg/kg) administration in TNBS-induced colitis in rats (p=0.021, p=0.026, p=0.019, 
p=0.031, respectively). Colitis group was defined by the severe detriment of surface epithelium, submucosal edema and 
inflammatory cell infiltration. Treatment with GA significantly decreased inflammatory cell infiltration.
Conclusion: GA can be used as an effective agent in the treatment of colitis due to its inhibitory properties in multiple 
pathways and its potent antioxidant effects.
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INTRODUCTION
Ulcerative colitis (UC) is accepted as inflammatory bowel disease (IBD), and this disease is chronic inflammatory 
cases impressive the gastrointestinal system (1). UC is an idiopathic IBD with common, repetitive inflammation of 
the colon and rectum, which is highly defined by loss of blood on colon mucosa, ulceration and acute inflammation 
(2). Severe diarrhea, abdominal pain, cramping, chronic fatigue, weight loss and dermatological complications are 
the well-known symptoms of UC (3, 4). Etiopathology of UC is complicated, including bacterial or viral infection, 
the difference of colon microbiota, extreme immune reply, and oxidative stress damage. Oxidative stress has well-
known as an important pathogenic factor of UC (5, 6).
Lipid peroxidation is serious cellular damage and lipid peroxidation is formed by in the membrane, and attack-
ing by reactive oxygen species (ROS) would lead to high structural and functional differences on membranes 
(6). Myeloperoxidase (MPO), which is among powerful oxidant sources in the living system, is an enzyme that 
is secreted by neutrophils at a high rate, and monocyte, macrophage and kupffer cells at a lower rate (7). MPO 
supports oxidative stress in many inflammatory situations, and it utilized the hydrogen peroxide to catalyze the 
generation of potent oxidants containing chlorine bleach and free radicals (8). Cathepsins also play a consider-
able role in physiological events, such as the antigen presentation in the immune system, wound healing, bone 
remodelling, and reproduction, apart from the proteolytic activities (9). Cathepsin B and cathepsin L that are the 
members of the cysteine cathepsin family act as a part of the proteolytic cascade and are present in an active and 
stable state in acidic cell structures such as lysosomes and endosomes (10).
Gallic acid (3,4,5 trihydroxybenzoic acid) (GA) is a product available in some plants. GA is accepted to display 
of bioactivities with the inclusion of anticancer, antimicrobial, antioxidant, and anti-inflammatory (11, 12). We 
investigated the putative protective role of two doses of gallic acid on 2,4,6-trinitrobenzene sulfonic acid (TNBS)-
induced experimental colitis in rats.
MATERIALS AND METHODS
Chemicals 
Gallic acid (97.5%), TNBS and all other chemicals of analytical grade were purchased from Sigma Chemical Co. 
(St. Louis, MO).
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Animals
Twenty-eight adult male Sprague-Dawley rats (weighing between 
230±20 g) were carried from TICAM (Medical and Surgical Ex-
perimental Research Centre, Eskisehir) and were proceeded in a 
light- and temperature-controlled room. The animals were fed the 
standard pellet diet and drinking water overnight before TNBS ad-
ministration. The experimental method and application were con-
firmed by the Eskisehir Osmangazi University Institutional Ethical 
Committee for Animal Care (2009/21/127). 
Experimental Design
The rats were incidentally separated into four groups, each con-
taining seven animals. The first group was control healthy (C), the 
second group was colitis-untreated (Colitis), the third (Colitis-GA 
50 mg/kg) and the fourth groups (Colitis-GA 100 mg/kg) were 
colitis and GA treated at the doses of 50 and 100 mg/kg b.w., 
respectively (13). 
Induction of Colitis and Treatments
Rats are often starved overnight and colitis was formed by colonic 
application of 1 ml solution of 2,4,6-trinitrobenzene sulfonic acid 
(TNBS, 30 mg/ml in 50% ethanol) with an 8-cm cannula under 
mild ether anaesthesia (14).
One day after following the created of colitis; GA (at the doses of 
50 and 100 mg/kg b.w., dissolved with saline 2 ml/kg volume) or 
saline (2 ml/kg volume) was given orally one time a day for seven 
days. At the end of seventh-day, an overnight fasting all the test an-
imals were decapitated. The last 8 cm of the colon was cut, opened 
longitudinally, and washed with saline solution. Samples of colon 
tissue were obtained from the distal colon area were preserved at 
−20°C for next analsis of malondialdehyde (MDA), MPO, cathep-
sin B and cathepsin L levels. 
Biochemical Analysis
Colon tissue protein was assayed by the method of bradford pro-
tein assay (15), using serum bovine albumin as standard. The MPO 
activity was performed using the spectrophotometrically method 
by measuring the transformation of taurine totaurine mono-chlo-
ramine using the 2-nitro-5-thiobenzoic acid (TNB) analysis (16). 
TNB reagent was presented by dissolving 5,5′-Dithiobis-2-ni-
trobenzoic acid (DTNB) in aqueous 0.05 M sodium hydroxide solu-
tion to make a final concentration of 1 mM DTNB and then dilut-
ing 1:40 into 0.1 M phos-phate buffer (pH 7.4). The absorbances 
were read at 412 nm wavelength. MPO activitiy was presented as 
U/mg protein. 
The MDA levels were analyzed using the spectrophotometric 
method of thiobarbituric acid (TBA) test. A total of 500 µl of the 
homogenate was reacted with 250 µl of trichloroacetic acid (TCA) 
20% for deproteination. The samples were vortexed and all sam-
ples were centrifuged at a 5000x rpm for 10 minutes. The super-
natants were taken, and 500 µl TBA 0.67% was added. The sam-
ples were vortexed and incubated in a water heater at 96°C, 10 
minutes and cool at room temperature, then, read the absorbances 
at a wavelength of 530 nm (17). MDA levels were presented as 
nmol/mg protein.
Activities of cathepsin B and cathepsin L were analyzed with a gen-
eral procedure utilizing methylcoumarylamide substrates. Fluores-
cence was determined on a Jasco fluorescence spectrometer with 
a caution wavelength set to 360 nm and distribution wavelength 
set to 460 nm provided the density/5 min using the maximum lin-
ear rate for both the test and blank (13). Cathepsin activities were 
stated as ng/mg protein.
Histological Evaluation of Colonic Damage
For light microscopic assay, tissue samples (1 cm2 specimen at 8 
cm from anus was provided from all rat) were fixed in 10% neu-
tral formaldehyde solution and performed by usual methods before 
embedding in paraffin. Part of tissue was cut at 5 µm on a revolving 
microtome, affixed on slides, stained with standard H&E. Tissues 
were studied under an Olympus CX31 photomicroscope. Every 
tissue parts were investigated microscopically for description of 
histopathological differences. 
Statistical Analysis
Analyses of all data were performed using Statistical Package for 
the Social Sciences (SPSS) for Windows 16.0 package program 
(SPSS Inc., Chicago, IL, USA). Kolmogorov-Smirnov and Shapiro-
Wilk tests were used to evaluate the distribution of continuous 
variables. Continuous normally distributed measurements were 
compared across the groups using one-way analysis of variance 
(ANOVA) with the Tukey method and the Student–Newman–Keuls 
method multiple comparisons. The descriptive statistics demon-
strated the mean and standard deviation (S.D) for continuous vari-
ables. All differences were accepted significant at p<0.05.
RESULTS
Biochemical Results
The results of the experimental groups are presented in Table 1. 
When we compared our study groups, we observed that tissue 
Table 1. Biochemical results of the groups
 MDA MPO Cathepsin B Cathepsin L 
 (nmol/mg protein) (U/mg protein) (ng/mg protein) (ng/mg protein)
Control 2.69±0.35 2.02±0.38 3.86±0.60 10.02±1.94
Colitis 4.29±0.74a 18.48±7.19a 7.47±1.12a 13.70±2.25a
Colitis-GA 50 mg/kg 4.03±1.19 16.76±6.58 5.13±2.77 12.39±5.41
Colitis-GA 100 mg/kg 3.02±0.49b 7.86±5.12b 4.99±1.48b 10.95±2.75b
Results are expressed as mean±SD. a: Significantly different when compared with the control group, (p<0.05); b: Significantly different when compared with colitis group, 
(p<0.05); MDA: Malondialdehyde; MPO: Myeloperoxidase
Bayramoğlu et al. Experimental ColitisErciyes Med J 2020; 42(2): 213–7 215
MDA (p=0.028), cathepsin L (p=0.024) and cathepsin B levels 
(p=0.019) with MPO (p=0.038) activity of the colitis group rose 
significantly in comparison to the control group. The dose of 100 
mg/kg GA decreased tissue levels of MDA, cathepsin L and cathep-
sin B and activity of MPO enzyme concerning the colitis group, sta-
tistically significantly at p=0.021, p=0.019, p=0.031, p=0.026, 
respectively. However, the dose of 50 mg/kg GA decreased tissue 
levels of MDA, cathepsin L and cathepsin B and activity of MPO 
enzyme concerning the colitis group, but there were no statistically 
significant (p=0.299, p=0.169, p=0.431, p=0.634, respectively). 
The results displayed that post-treatment to colitis rats with GA, 
especially at a dose of 100 mg/kg, partially reduced the colonic 
damage induced TNBS.
Histological Results
The control group was described as normal morphology. TNBS 
caused significant macroscopic colonic tissue damage. The coli-
tis group was defined by the severe detriment of surface epithe-
lium, submucosal edema and inflammatory cell infiltration (Fig. 1). 
Treatment with 50 and 100 mg/kg of GA significantly decreased 
inflammatory cell infiltration. At a dose of 50 mg/kg of GA group, 
we observed mild inflammatory cell infiltration, regenerated glands 
and mild edema.
At a dose of 100 mg/kg of GA group, regular surface epithelium, 
described nearly a normal histological morphology, was observed. 
All doses of GA showed significantly positive effects on the TNBS-
induced colitis model (Fig. 2).
DISCUSSION
Inflammatory bowel disease is a systemic disease, which involves 
the gastrointestinal system, of which etiology is not known com-
pletely and which affects the life quality of the patient significantly 
(18). Prenatal events, lactation, childhood infectious diseases, mi-
crobial factors, smoking, oral contraceptives, nutrition, cleaning, 
business, education, environment terms, stress, psychological fac-
tors and physical activity may play a role in the progress of ulcera-
tive colitis (19, 20). In this study, to answer this question, we have 
now evaluated the effects of a TNBS induced colonic inflammation 
on colon cathepsin B/cathepsin L pathway, together with the lipid 
peroxidation and MPO activity, and the possible preventive effects 
of administration of gallic acid on these parameters.
TNBS-induced colitis is characterized by oxidative stress and up-
regulation of proinflammatory cytokines. The present study has 
demonstrated that TNBS causes an upregulation of levels of MDA, 
cathepsin B, cathepsin L and MPO activity. The levels of MDA, 
MPO and cathepsins were fundamentally reduced in rats treated 
with all the doses of gallic acid, but of all the doses, 100 mg/kg/
day gallic acid dose was most effective and the results were statis-
tically significant.
MDA is a product of the lipid peroxidation that comes about as 
a result of colonic damage. Lipid peroxidation causes cross-link-
ing of nucleic acid molecules and protein. As a result, MDA is 
cytotoxic for the cell. Joo et al. (21) have indicated that TNBS-
induced colitis is associated with increased MDA levels in rats, 
and diverse flavonoids used in the treatment of colitis disease can 
reduce levels of MDA in colon tissues. Another study, Yildiz et al. 
(22), induced colonic inflammation with intra-rectal administra-
tion of TNBS and MDA levels were increased in colonic tissue. 
Lee et al. (23) suggested that TNBS causes lipid peroxidation in 
the colon, which may cause colitis and ROS may substantially be 
related to the pathogenesis of inflammatory bowel diseases. In 
our study, TNBS was observed to increase the MDA levels, which 
was compatible with the literature.
MPO, a basic ingredient of neutrophil azurophilic granules, is a 
good parameter of inflammation and tissue damage. MPO is an 
important enzyme that ensures the formation of free oxygen radi-
cals. The accumulation of neutrophils in the area where oxidative 
damage occurs causes an increase in tissue MPO activity (24, 25). 
Miroliaee et al. (26) suggested that among diverse parameters of 
oxidative stress, evaluation of MPO with lipid peroxidation and 
antioxidant power is sufficient in making a correlation with the 
seriousness of colitis. In another experimental study, Ghasemi-Pir-
baluti et al. (27) used acetic acid for colitis model in rat and they 
observed to increase in MPO activity in colonic tissue. In this study, 
MPO activity in the colitis group was statistically higher than in the 
control group.
Figure 1. The control group was described as normal mor-
phology. Colitis group; it was characterized by a massive 
loss of surface epithelium, submucosal edema and inflam-
matory cell infiltration
Figure 2. Gallic acid (50 mg/kg) colitis treated group: Mild 
inflammatory cell infiltration, regenerated glands and mild 
edema. Gallic acid (100 mg/kg) colitis treated group: regu-
lar surface epithelium, describe nearly a normal histologi-
cal morphology
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UC has a great prevalence global and is accepted as a risk factor of 
colon cancer. Hence, recent therapeutical agent and approaches 
for UC need to be improved. GA is a polyhydroxy phenolic com-
pound that has been come across in multiple natural resources. 
GA is powerful antioxidant and it has anti-inflammatory properties 
(28). Our study has demonstrated that 100 mg/kg gallic acid dose 
significantly restrict experimental colitis-associated production of 
MPO and MDA.
Cathepsins can play a considerable mission in the regulation of 
apoptosis. The proteolytic and disruptive features of the lysosomal 
cathepsins have been indicated to a major role in chronic inflamma-
tory diseases (29). The expressions of cathepsin B and cathepsin L 
increase in inflammatory bowel diseases and this increase occurs, 
particularly in the fields of tissue damage and mucosal ulceration. 
The researchers also put forth in their study that the inhibition of 
cathepsins is related to the level of inflammation, and cathepsin in-
hibitors may be effective in the treatment of inflammatory bowel dis-
eases (30). In this study, a significant increase occurred in cathepsin 
B and cathepsin L levels in colonic inflammation induced by TNBS 
when compared to the control group. Our results also now showed 
to a pathophysiological role of cathepsins in TNBS-induced colonic 
inflammation. Additionally, a significant decrease was observed in 
the levels of cathepsins in a dose of 100 mg/kg GA that we used 
for treatment purposes. GA application was reduced extrication of 
lysosomal cathepsin B and L enzymes into the cytoplasmic piece 
and obstructed TNBS-induced colitis. Our histopathologic results 
indicated that TNBS induced colitis and we observed severe harm 
of surface epithelium, submucosal edema and inflammatory cell 
infiltration in colitis group. However, we evaluated to histological 
results; all doses of GA have positive effects of colonic tissue. In the 
dose of 50 mg/kg GA group, we observed mild inflammatory cell 
infiltration, regenerated glands and mild edema. In 100 mg/kg GA 
group, we observed regular surface epithelium, describe nearly a 
normal histological morphology in colon tissue.
CONCLUSION
Cathepsins are entirely identified as important diagnostic and ther-
apeutic goal exceedingly for the UC. Their various functions pose 
a problem in the design of successful vehicles for their therapeu-
tic targeting, as proved by the systematic failure of many cathep-
sin inhibitors in clinical tests (30). We found that treatment with 
GA significantly ameliorated TNBS-induced colitis generation of 
cathepsin activities and oxidative stress. The preventive effects of 
gallic acid might be effective therapeutic target on cathepsin activ-
ities in ulcerative colitis.
Ethics Committee Approval: The experimental method and applica-
tion were confirmed by the Eskişehir Osmangazi University Institutional 
Ethical Committee for Animal Care (date: 19.08.2009, number: 127). 
All procedures performed in studies involving animals were in accordance 
with the ethical standards of the institution or practice at which the studies 
were conducted.
Peer-review: Externally peer-reviewed.
Author Contributions: Concept – GB, HŞ; Design – GK, MC; Supervi-
sion – MC, GB; Resource – GB, GK; Materials – GB, HŞ; Data Collection 
and/or Processing – ED, GB; Analysis and/or Interpretation – AB, ED; 
Literature Search – SE, ED Writing – ED, AB; Critical Reviews – GB, HŞ.
Conflict of Interest: The authors have no conflict of interest to declare.
Financial Disclosure: The authors declared that this study has received 
no financial support.
REFERENCES
1. Mi H, Liu FB, Li HW, Hou JT, Li PW. Anti-inflammatory effect of 
Chang-An-Shuan on TNBS-induced experimental colitis in rats. BMC 
Complement Altern Med 2017; 17(1): 315. [CrossRef]
2. Bai X, Gou X, Cai P, Xu C, Cao L, Zhao Z, et al. Sesamin Enhances 
Nrf2-Mediated Protective Defense against Oxidative Stress and Inflam-
mation in Colitis via AKT and ERK Activation. Oxid Med Cell Longev 
2019; 2019: 2432416. [CrossRef]
3. Jelsness-Jørgensen LP, Bernklev T, Henriksen M, Torp R, Moum BA. 
Chronic fatigue is more prevalent in patients with inflammatory bowel 
disease than in healthy controls. Inflamm Bowel Dis 2011; 17(7): 
1564–72. [CrossRef]
4. Teruel C, Garrido E, Mesonero F. Diagnosis and management of func-
tional symptoms in inflammatory bowel disease in remission. World J 
Gastrointest Pharmacol Ther 2016; 7(1): 78–90. [CrossRef]
5. Wang Z, Li S, Cao Y, Tian X, Zeng R, Liao DF, et al. Oxidative Stress 
and Carbonyl Lesions in Ulcerative Colitis and Associated Colorectal 
Cancer. Oxid Med Cell Longev 2016; 2016: 9875298. [CrossRef]
6. Pereira C, Grácio D, Teixeira JP, Magro F. Oxidative Stress and DNA 
Damage: Implications in Inflammatory Bowel Disease. Inflamm Bowel 
Dis 2015; 21(10): 2403–17. [CrossRef]
7. Aratani Y. Myeloperoxidase: Its role for host defense, inflammation, 
and neutrophil function. Arch Biochem Biophys 2018; 640: 47–52.
8. Chapman AL, Mocatta TJ, Shiva S, Seidel A, Chen B, Khalilova I, et 
al. Ceruloplasmin is an endogenous inhibitor of myeloperoxidase. J 
Biol Chem 2013; 288(9): 6465–77. [CrossRef]
9. Petushkova AI, Savvateeva LV, Korolev DO, Zamyatnin AA Jr. Cysteine 
Cathepsins: Potential Applications in Diagnostics and Therapy of Malig-
nant Tumors. Biochemistry (Mosc) 2019; 84(7): 746–61. [CrossRef]
10. Li YY, Fang J, Ao GZ. Cathepsin B and L inhibitors: a patent review 
(2010 - present). Expert Opin Ther Pat 2017; 27(6): 643–56. [CrossRef]
11. Fernandes FH, Salgado HR. Gallic Acid: Review of the Methods of 
Determination and Quantification. Crit Rev Anal Chem 2016; 46(3): 
257–65. [CrossRef]
12. Choubey S, Varughese LR, Kumar V, Beniwal V. Medicinal impor-
tance of gallic acid and its ester derivatives: a patent review. Pharm Pat 
Anal 2015; 4(4): 305–15. [CrossRef]
13. Kanbak G, Canbek M, Oğlakçı A, Kartkaya K, Sentürk H, Bayramoğlu 
G, et al. Preventive role of gallic acid on alcohol dependent and cys-
teine protease-mediated pancreas injury. Mol Biol Rep 2012; 39(12): 
10249–55. [CrossRef]
14. Cetinel S, Hancioğlu S, Sener E, Uner C, Kiliç M, Sener G, et al. 
Oxytocin treatment alleviates stress-aggravated colitis by a receptor-de-
pendent mechanism. Regul Pept 2010; 160(1-3): 146–52. [CrossRef]
15. Ernst O, Zor T. Linearization of the bradford protein assay. J Vis Exp 
2010; (38): 1918. [CrossRef]
16. Maiocchi SL, Morris JC, Rees MD, Thomas SR. Regulation of the 
nitric oxide oxidase activity of myeloperoxidase by pharmacological 
agents. Biochem Pharmacol 2017; 135: 90–115. [CrossRef]
17. Tualeka AR, Martiana T, Ahsan A, Russeng SS, Meidikayanti W. As-
sociation between Malondialdehyde and Glutathione (L-gamma-Glu-
tamyl-Cysteinyl-Glycine/GSH) Levels on Workers Exposed to Benzene 
in Indonesia. Open Access Maced J Med Sci 2019; 7(7): 1198–202. 
18. Sairenji T, Collins KL, Evans DV. An Update on Inflammatory Bowel 
Disease. Prim Care 2017; 44(4): 673–92. [CrossRef]
19. Bernstein CN. Assessing environmental risk factors affecting the in-
Bayramoğlu et al. Experimental ColitisErciyes Med J 2020; 42(2): 213–7 217
flammatory bowel diseases: a joint workshop of the Crohn’s & Colitis 
Foundations of Canada and the USA. Inflamm Bowel Dis 2008; 14(8): 
1139–46. [CrossRef]
20. Rana SV, Sharma S, Prasad KK, Sinha SK, Singh K. Role of oxidative 
stress & antioxidant defence in ulcerative colitis patients from north 
India. Indian J Med Res 2014; 139(4): 568–71.
21. Joo M, Kim HS, Kwon TH, Palikhe A, Zaw TS, Jeong JH, et al. Anti-
inflammatory Effects of Flavonoids on TNBS-induced Colitis of Rats. 
Korean J Physiol Pharmacol 2015; 19(1): 43–50. [CrossRef]
22. Yildiz G, Yildiz Y, Ulutas PA, Yaylali A, Ural M. Resveratrol Pretreat-
ment Ameliorates TNBS Colitis in Rats. Recent Pat Endocr Metab Im-
mune Drug Discov 2015; 9(2): 134–40. [CrossRef]
23. Lee IA, Hyun YJ, Kim DH. Berberine ameliorates TNBS-induced col-
itis by inhibiting lipid peroxidation, enterobacterial growth and NF-κB 
activation. Eur J Pharmacol 2010; 648(1-3): 162–70. [CrossRef]
24. Mancini S, Mariani F, Sena P, Benincasa M, Roncucci L. Myeloperoxi-
dase expression in human colonic mucosa is related to systemic oxida-
tive balance in healthy subjects. Redox Rep 2017; 22(6): 399–407.
25. Nauseef WM. Biosynthesis of human myeloperoxidase. Arch Biochem 
Biophys 2018; 642: 1–9. [CrossRef]
26. Miroliaee AE, Esmaily H, Vaziri-Bami A, Baeeri M, Shahverdi AR, Ab-
dollahi M. Amelioration of experimental colitis by a novel nanoseleni-
um-silymarin mixture. Toxicol Mech Methods 2011; 21(3): 200–8.
27. Ghasemi-Pirbaluti M, Motaghi E, Najafi A, Hosseini MJ. The effect of 
theophylline on acetic acid induced ulcerative colitis in rats. Biomed 
Pharmacother 2017; 90: 153–9. [CrossRef]
28. Pandurangan AK, Mohebali N, Norhaizan ME, Looi CY. Gallic acid 
attenuates dextran sulfate sodium-induced experimental colitis in 
BALB/c mice. Drug Des Devel Ther 2015; 9: 3923–34. [CrossRef]
29. Gondi CS, Rao JS. Cathepsin B as a cancer target. Expert Opin Ther 
Targets 2013; 17(3): 281–91. [CrossRef]
30. Vidak E, Javoršek U, Vizovišek M, Turk B. Cysteine Cathepsins and 
their Extracellular Roles: Shaping the Microenvironment. Cells 2019; 
8(3): 264. [CrossRef]
